Sugi Predict

Sugi Predict / Compounds / SCHEMBL2939631

SCHEMBL2939631

SCHEMBL2939631

CC1C(=O)N(c2ccc(S(=O)(=O)C(F)(F)F)cc2)C(=O)N1Cc1ccncc1NC(=O)c1ccco1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 2/20 0.57
▸ ALDH1A1 P00352 5/20 0.37
▸ LMNA P02545 2/20 0.37
▸ HTT P42858 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ SMO Q99835 2/20 0.36
▸ NAMPT P43490 1/20 0.36
▸ SRPK1 Q96SB4 2/20 0.35
▸ ALOX15 P16050 2/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ MEN1 O00255 3/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.34
▸ POLB P06746 2/20 0.34
▸ HPGD P15428 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ RXFP1 Q9HBX9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2941779 0.88 IGF1R (0.61) IGF1RALDH1A1LMNASMN1; SMN2SMO
SCHEMBL2939117 0.87 IGF1R (0.41) IGF1RALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL2935154 0.87 IGF1R (0.41) IGF1RALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL2939954 0.86 IGF1R (0.60) IGF1RALDH1A1LMNASMONAMPT
SCHEMBL2940490 0.86 IGF1R (0.61) IGF1RALDH1A1LMNASMONAMPT
SCHEMBL2937893 0.86 IGF1R (0.62) IGF1RSMONAMPTRXFP1
SCHEMBL2938404 0.85 IGF1R (0.55) IGF1RALDH1A1LMNAKDM4EHSD17B10
SCHEMBL2939601 0.85 IGF1R (0.59) IGF1RSMONAMPT
SCHEMBL2938772 0.85 IGF1R (0.57) IGF1RALDH1A1LMNASMN1; SMN2SMO
SCHEMBL2934036 0.85 IGF1R (0.55) IGF1RLMNASMN1; SMN2KDM4ESMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 — — EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 IGF1R 1595/4885ALDH1A1 3413/4885LMNA 1988/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA IGF1R 962/4885ALDH1A1 2827/4885LMNA 2970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.